Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Takes Over Adderall IR From Shire

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC waiting period over, Barr will acquire the branded immediate-release version, but does not plan to promote it.

You may also be interested in...



Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity

The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.

Teva Generic Versions Of Focalin Clear FDA With 180-Day Exclusivity

The approval includes 2.5 mg, 5 mg and 10 mg formulations of dexmethylphenidate tabs for ADHD.

Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009

Questions over whether the deal will pass FTC muster demonstrate how jittery industry is becoming following a criminal probe into a Sanofi/Bristol agreement.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel